AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (aBC). In AMEERA-3 (ClinicalTrials....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2023-08, Vol.41 (24), p.4014-4024
Hauptverfasser:	Tolaney, Sara M, Chan, Arlene, Petrakova, Katarina, Delaloge, Suzette, Campone, Mario, Iwata, Hiroji, Peddi, Parvin F, Kaufman, Peter A, De Kermadec, Elisabeth, Liu, Qianying, Cohen, Patrick, Paux, Gautier, Wang, Lei, Ternès, Nils, Boitier, Eric, Im, Seock-Ah
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast Neoplasms - pathology Female Humans ORIGINAL REPORTS Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!